AU2018219967A1 — Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Assigned to Les Laboratoires Servier SAS · Expires 2018-09-13 · 8y expired
What this patent protects
The present application relates to a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1 yl)methyl-2,4-(lH,3H)-pyrimidinedione hydrochloride. The present application provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4-(lH,3H)-pyrimidinedione hydrochloride havin…
USPTO Abstract
The present application relates to a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1 yl)methyl-2,4-(lH,3H)-pyrimidinedione hydrochloride. The present application provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4-(lH,3H)-pyrimidinedione hydrochloride having characteristic peaks at diffraction angles (20+0.1 ) of 11.60, 17.20, 17.80, 23.30, 27.10 and 29.3' in powder X-ray diffraction.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.